Lin S R, Chang S C, Lee C C, Shen M C, Lin S W
Graduate Institute of Medical Technology, National Taiwan University, School of Medicine, Taipei, R.O.C.
Br J Haematol. 1995 Nov;91(3):722-7. doi: 10.1111/j.1365-2141.1995.tb05375.x.
Genetic diagnosis of haemophilia A has been studied in two aspects. One is to directly identify the mutations in the factor VIII genes of the affected probands, and the other is to examine the usefulness of several intragenic factor VIII markers for gene tracking. Direct mutational analysis by PCR-SSCP (polymerase chain reaction--single-strand conformation polymorphism) has been accomplished previously in 87 haemophilia A patients, accounting for nearly 10% of cases in Taiwan. Of the 87 cases, 46% were with point mutations, short deletions or insertions, and most of the remaining were with gene inversion readily identified by Southern blotting. Further examination of 112 patients has estimated a 33% incidence for gene inversion in all the patients with haemophilia A, or 37% in severe cases. Since the direct mutational detection described above cannot be used in all Chinese families with haemophilia A, genetic markers were also investigated. The two CA repeat markers located at intron 13 (CA-13) and intron 22 (CA-22), respectively, were amplified and analysed simultaneously. Seven different alleles with 18-24 CAs have been identified for CA-13. Alleles of 20 and 21 CAs are the most common and their population frequency was 0.68 and 0.24, respectively. The CA-22 marker contained a repetition of (GT)n(AG)n as was identified in the white European but not in the Canadian population. Alleles with 25 and 26 GT/AGs account for 18% and 75% of this group of samples, respectively. The expected rate of heterozygosity for either CA markers was 68%, although a value of 57% was observed by haplotype analysis, indicating an association of the two repeat markers. Nevertheless, the study of 62 females showed that with the combined use of CA-13 and CA-22 with BclI, approximately 71% would be informative for these markers. This number may increase to 81% if XbaI polymorphism is added. We propose that a better genetic diagnosis procedure for Chinese individuals would be first to look for the inversion mutation, secondly for one of the intragenic markers, and then at the PCR-SSCP analysis.
对甲型血友病的基因诊断进行了两方面的研究。一是直接鉴定受影响先证者凝血因子VIII基因中的突变,二是检测几种基因内凝血因子VIII标记物用于基因追踪的效用。此前已通过聚合酶链反应-单链构象多态性(PCR-SSCP)对87例甲型血友病患者进行了直接突变分析,占台湾病例的近10%。在这87例病例中,46%存在点突变、短缺失或插入,其余大多数通过Southern印迹法可轻易鉴定出基因倒位。对另外112例患者的进一步检查估计,所有甲型血友病患者中基因倒位的发生率为33%,重症患者中为37%。由于上述直接突变检测方法不能用于所有中国甲型血友病家庭,因此也对基因标记物进行了研究。分别位于内含子13(CA-13)和内含子22(CA-22)的两个CA重复标记物被同时扩增和分析。已鉴定出CA-13有7种不同的等位基因,其CA重复数为18 - 24个。CA重复数为20和21的等位基因最为常见,其群体频率分别为0.68和0.24。CA-22标记物包含(GT)n(AG)n重复序列,这在白种欧洲人中已被鉴定出,但在加拿大人群中未发现。CA重复数为25和26的GT/AG等位基因分别占该组样本的18%和75%。尽管通过单倍型分析观察到的杂合度值为57%,但两种CA标记物的预期杂合度率均为68%,表明这两个重复标记物之间存在关联。然而,对62名女性的研究表明,联合使用CA-13、CA-22和BclI,约71%的个体对这些标记物具有信息价值。如果加入XbaI多态性,这一数字可能会增至81%。我们建议,针对中国个体更好的基因诊断程序是,首先寻找倒位突变,其次寻找基因内标记物之一,然后进行PCR-SSCP分析。